Bafna Pharmaceuticals Limited has submitted to the Exchange, the outcome of the Board Meeting held on February 11, 2026 along with the Unaudited financial results and Limited Review Report for the Quarter and Nine Months ended December 31, 2025.
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bafna Pharmaceuticals has informed the stock exchange about the outcome of its Board Meeting held on February 11, 2026. The company submitted its unaudited financial results for the quarter ending December 31, 2025 (Q3 FY26), along with the Limited Review Report from its auditors. The filing also covers results for the nine-month period ending December 31, 2025. No specific financial figures such as revenue, profit, or margins have been disclosed in this headline announcement. Investors will need to refer to the detailed results document for actual numbers.
This is a standard regulatory filing confirming that quarterly results were approved by the Board; the actual business impact depends on the numbers in the detailed results, which are not provided here. Shareholders should review the full results for any surprises in revenue, profit, or margins.